MRKR Stock Overview
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Marker Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.14 |
| 52 Week High | US$5.99 |
| 52 Week Low | US$1.83 |
| Beta | 1.49 |
| 1 Month Change | -38.68% |
| 3 Month Change | -50.46% |
| 1 Year Change | -51.25% |
| 3 Year Change | -61.72% |
| 5 Year Change | -91.74% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04
Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Marker shares rise as it completes construction of its cGMP manufacturing facility
Jan 13FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy
Jan 05Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29Marker Therapeutics EPS misses by $0.02
Nov 09Shareholder Returns
| MRKR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.0% | 3.6% | 1.8% |
| 1Y | -51.3% | -3.7% | 24.9% |
Return vs Industry: MRKR underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: MRKR underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| MRKR volatility | |
|---|---|
| MRKR Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MRKR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MRKR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Juan Vera | markertherapeutics.com |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. Fundamentals Summary
| MRKR fundamental statistics | |
|---|---|
| Market cap | US$22.91m |
| Earnings (TTM) | -US$9.63m |
| Revenue (TTM) | US$5.40m |
4.2x
P/S Ratio-2.4x
P/E RatioIs MRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRKR income statement (TTM) | |
|---|---|
| Revenue | US$5.40m |
| Cost of Revenue | US$11.00m |
| Gross Profit | -US$5.60m |
| Other Expenses | US$4.03m |
| Earnings | -US$9.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | -103.84% |
| Net Profit Margin | -178.54% |
| Debt/Equity Ratio | 0% |
How did MRKR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/26 21:22 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marker Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yun Zhong | Janney Montgomery Scott LLC |
| Aydin Huseynov | Ladenburg Thalmann & Company |